Trial reportHeart (British Cardiac Society)2012
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes.
Trial report in Heart (British Cardiac Society), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Exploring the Clinical Utility of Osteoprotegerin in Heart Failure-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants.Journal of the American Heart Association · 2018Pooled it
- Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.Journal of the American Heart Association · 2018Trial
- Growth Differentiation Factor-15 in Acute Coronary Syndromes: Prognostic Value and Barriers to Clinical Implementation.International journal of molecular sciences · 2026Review
- Systemic inflammatory response drives post-cardiac arrest multi-organ injury via IL-17 signaling in murine and porcine models.Frontiers in immunology · 2026Article
- Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Article
- Tumor Necrosis Factor Family Members and Myocardial Ischemia-Reperfusion Injury: State of the Art and Therapeutic Implications.International journal of molecular sciences · 2023Review
- Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial.Frontiers in cardiovascular medicine · 2023Article
- Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.Heart failure reviews · 2022Review
- Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes.Journal of thrombosis and thrombolysis · 2022Article
- Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study.PLoS medicine · 2021Article
- The relevance of microRNA in post-infarction left ventricular remodelling and heart failure.Heart failure reviews · 2019Review
- Neuroendocrine System Regulatory Mechanisms: Acute Coronary Syndrome and Stress Hyperglycaemia.European cardiology · 2018Review
- Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population.Current heart failure reports · 2017Review
- Osteoprotegerin Gene (OPG) Polymorphisms Associated with Peri-implantitis Susceptibility in a Chinese Han Population.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Association of gene polymorphisms in RANKL/RANK/OPG system with hypertension and blood pressure in Chinese women.Journal of human hypertension · 2015Article
- Cardiac arrest: resuscitation and reperfusion.Circulation research · 2015Review
- Review
- New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.Journal of cardiovascular translational research · 2013Review
- Association of bone turnover markers with mortality in men referred to coronary angiography.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the relationship between osteoprotegerin (OPG) and cardiovascular death, and the pathobiological mechanisms contributing to the association, in acute coronary syndromes (ACS).
designProspective observational.
settingBiomarker substudy of MERLIN-TIMI 36, a randomised, placebo controlled trial of ranolazine in non-ST elevation (NSTE)-ACS. PATIENTS: 4463 patients with NSTE-ACS.
interventionsRanolazine or placebo.
main outcome measuresIncidence of cardiovascular death (CV death); additionally, heart failure (HF), cardiac arrhythmias, in-hospital ischaemia, severe recurrent ischaemia or recurrent myocardial infarction (MI).
resultsDuring a median follow-up of 341 days, 208 patients died of cardiovascular causes. The OPG baseline concentration was strongly associated with both 30 day and 1 year incidence of CV death. After adjustment for conventional risk markers, OPG concentrations (log transformed) remained a significant predictor of CV death by 30 days (HR (95% CI) 2.32 (1.30 to 4.17); p=0.005) and by 1 year (HR 1.85 (1.33 to 2.59); p<0.001). Baseline levels of OPG were also an independent predictor of new or worsening HF at 30 days (HR 2.25 (1.38 to 3.69); p=0.001) and 1 year (HR 1.81 (1.26 to 2.58) p=0.001). By univariable analysis, higher OPG was associated with both early ischaemic and arrhythmic events. Although OPG levels were associated with recurrent MI within 12 months, this association was attenuated and no longer significant after multivariable adjustment.
conclusionsOPG is independently associated with 30 day and 1 year risk of cardiovascular mortality and HF development after NSTE-ACS. As no independent relationship between OPG levels and recurrent ischaemia or MI was observed, myocardial dysfunction may be a more important stimulus for OPG production than ischaemia in ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.